|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the incidence, timing, and characteristics of stent thrombosis and its consequences in patients with atrial fibrillation (AF) in the AUGUSTUS trial<sup>1</sup> who received a coronary stent during their qualifying admission (acute coronary syndrome [ACS] or elective percutaneous coronary intervention [PCI]) and the randomized treatment effects of low-dose aspirin (compared with placebo) and apixaban (compared with vitamin K antagonist [VKA]) on the risk of stent thrombosis.
|
31707833 |
2020 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The endpoints were acute coronary syndrome and re-admission for revascularization (PCI or coronary artery bypass graft surgery) after 3, 6, and 12 months.
|
31371901 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our population is represented by a consecutive cohort ofdiabetic patients treated with DAPT (ASA + clopidogrel or ticagrelor or dose-adjusted prasugrel) for an acute coronary syndrome or elective PCI, undergoing platelet reactivity assessment at 30-90 days post-discharge.
|
31176855 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 56.1% patients underwent PCI for acute coronary syndrome (ACS).
|
30826192 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study.
|
31777468 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients referred for coronary angiography (N=88) or PCI (N=592) for stable angina or acute coronary syndrome, the SYNTAX score calculator (www.syntaxscore.com) was used to determine the SXscore before PCI, if applicable.
|
29537372 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the majority of patients undergoing PCI shifted from stable angina pectoris (SA) to acute coronary syndrome (ACS).
|
28992998 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> In 582 consecutive patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) scheduled for PCI and treated with ASA and Clopidogrel, Prasugrel, or Ticagrelor, SNP analysis for rs12566888, rs2768759, rs41273215, rs3737224, and rs822442 was performed.
|
29867494 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-two patients who underwent PCI using the Filtrap® for acute coronary syndrome (ACS) were enrolled.
|
29915959 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of RISK-PCI, GRACE, TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome.
|
29308832 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the impact of stent type on the risk of death or myocardial infarction (MI) related to dual antiplatelet therapy (DAPT) more than 12 months (prolonged DAPT) versus 12 or less months after PCI for an acute coronary syndrome (ACS).
|
27860195 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute coronary syndrome was the indication for index-PCI in 74% of the patients.
|
28836297 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
For patients with acute coronary syndromes or those who underwent coronary revascularisation with either PCI or CABG, long-term use of OMT improves clinical outcomes and prognosis.
|
28844035 |
2017 |